The FDA has approved olaparib (Lynparza®, AstraZeneca) for the adjuvant treatment of patients with deleterious or suspected deleterious germline BRCA–mutated, human epidermal growth factor receptor 2 (HER2)–negative high-risk early breast cancer who have previously received adjuvant or neoadjuvant chemotherapy. Olaparib is a poly–adenosine diphosphate ribose polymerase (PARP) inhibitor and is the first approved medication targeting BRCA mutations in early breast cancer. "Approximately 5% of unse...